We found that ANGPTL3 largely bound to HDL, and slightly bound to LDL in non-diabetic subjects and T2DM patients (Fig. 1A). To further verify the presence of ANGPTL3 in HDL, co-immunoprecipitation assays with anti-ANGPTL3 antibody were performed on the HDL lysate of non-diabetic subjects....
The role of Lipoprotein (a) cholesterol {Lp(a)-C}as an additional and/or independent risk factor for cardiovascular disease (CVD) is not clear. We evaluated the associations between Lp(a)-C and other CVD risk factors including plasma lipoprotein concentr
In turn, torcetrapib administration increased levels of high-density lipoprotein cholesterol by 72.1% and decreased LDL (by 24.9%), as compared with baseline; however, in patients receiving this potent CETP inhibitor, enhanced risk of cardiovascular events (HR ratio, 1.25; 95% CI 1.09–1.44; p ...